Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anecortave acetate plus verteporfin for exudative age-related macular degeneration with retino-choroidal anastomosis
2005-002912-73Phase 3Completed
- Sponsor
- UZ Leuven
- Start
- Aug 2005
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of anecortave and verteporfin in age-related macular degeneration (AMD), sponsored by UZ Leuven. Primary endpoints: Percentage of patients maintaining positive visual acuity outcome and Mean change from baseline in logMAR visual acuity score. Started Aug 2005; status: completed.
02
Drugs
anecortaveverteporfin
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2005-002912-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002912-73.